​
​

CervoMed Stock (NASDAQ:DFFN)

OwnershipFinancialsChart
CervoMed by TradingView

Previous Close

$3.99

52W Range

$4.14 - $14.37

50D Avg

$5.06

200D Avg

$7.07

Market Cap

$8.98M

Avg Vol (3M)

$47.81K

Beta

1.76

Div Yield

-

DFFN Company Profile

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

May 23, 2008

Website

DFFN Performance

DFFN Financial Summary

Dec 22Dec 21Dec 20
Revenue---
Operating Income$-15.97M$-24.68M$-15.97M
Net Income$-15.21M$-24.10M$-14.19M
EBITDA$-15.97M$-7.31M$-15.87M
Basic EPS$-7.46$-18.57$-19.76
Diluted EPS$-11.19$-18.57$-19.76

Fiscal year ends in Dec 22 | Currency in USD

Peer Comparison

TickerCompany
SLNOSoleno Therapeutics, Inc.
MNPRMonopar Therapeutics Inc.
NXTCNextCure, Inc.
PULMPulmatrix, Inc.
BPTHBio-Path Holdings, Inc.
CAPRCapricor Therapeutics, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
AKTXAkari Therapeutics, Plc
TENXTenax Therapeutics, Inc.
JAGXJaguar Health, Inc.
ACSTAcasti Pharma Inc.
CBIOGyre Therapeutics, Inc.
CLRBCellectar Biosciences, Inc.